Pharmaceutical News

RSS

Drug company warns of risk of liver problems with antidepressant

The warning about possible liver-related problems with the depression drug, Cymbalta, has been expanded and doctors are being cautioned against its use in chronic liver disease patients.

18 Oct 2005

Ebixa (memantine) approved for the treatment of moderate Alzheimer's disease

The Committee for Medicinal Products for Human Use (CHMP) has announced its decision to extend Ebixa’s current indication (moderately severe to severe disease) to include moderate stages of Alzheimer’s disease (AD).

16 Oct 2005

Remicade can improve psoriasis symptoms

An international team led by a dermatologist at The University of Manchester has found that treatment with the emerging drug infliximab, marketed as Remicade, can quickly and significantly improve psoriasis symptoms.

From The University of Manchester 13 Oct 2005

Myriad Genetics nears completion of antithrombin drug trial

Myriad Genetics announced today that it is rapidly nearing completion of the preclinical data package on MPC-0920, its antithrombin drug candidate, for submission to the FDA prior to beginning human clinical trials.

11 Oct 2005

100% efficacy for cervical cancer vaccine

Final-stage clinical trials of a cervical cancer vaccine developed by University of Queensland (UQ) scientists, have shown the drug to be 100 per cent effective.

10 Oct 2005

Artemisinin combination therapies have potential to be one of the major public health interventions for Africa in this decade

Despite changes in policy in many African countries, most cases of malaria are still treated with old drugs that often fail, say researchers the British Medical Journal.

3 Oct 2005

Governments considering reclassifying some drugs from prescription to over-the-counter status

Governments in several countries with public Pharmacare and in a few provinces in Canada are considering reclassifying some drugs from prescription to over-the-counter status. In a Canadian Medical Association Journal essay, Lynd and colleagues comment on the economic effects of such changes.

27 Sep 2005

Increlex - first major innovation in 20 years for the treatment of growth failure

Rush University Medical Center is participating in a clinical trial to evaluate the potential benefit of the first major innovation in 20 years for the treatment of growth failure.

26 Sep 2005

CytRx granted "Fast Track" designation for ALS drug

CytRx Corporation today announced that the U.S. Food and Drug Administration (FDA) has granted "Fast Track" designation for the company's leading drug candidate arimoclomol for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease).

26 Sep 2005

Potential oral drug for rheumatoid arthritis

A potential oral drug for rheumatoid arthritis (RA) may encourage women to treat their condition earlier rather than later because it is less arduous than currently available treatments. Early treatment is important because RA most often develops between the ages of 35 and 50 and is two- to three times more prevalent in women.

26 Sep 2005

Important new lessons learned from aspirin

No other medicine is as common, inexpensive, and yet powerful in so many ways as aspirin; yet despite a century of experience with the drug, researchers are still learning important new lessons, while raising new questions, according to seven special articles in the Sept. 20, 2005, issue of the Journal of the American College of Cardiology.

20 Sep 2005

Making practical markets for vaccines

Two papers published on September 13 in PLoS Medicine raise concerns about whether world leaders are getting good advice on how best to fund the development and delivery of new vaccines.

19 Sep 2005

Drug AMD-3100 may help cancer patients who need stem cell transplants

A new drug may help cancer patients mobilize the cells necessary to restore their blood-forming system after high-dose chemotherapy, according to results from a clinical trial at the Kimmel Cancer Center at Thomas Jefferson University Hospital in Philadelphia and at other centers across the nation.

19 Sep 2005

Helix receives approval to conduct a clinical trial of Topical Interferon Alpha-2b in Sweden

Helix BioPharma today announced that it has received approval from Sweden's drug regulatory authority, the Medical Products Agency (MPA), to conduct a Phase II clinical trial of Topical Interferon Alpha-2b in patients with ano-genital warts (condylomata acuminata), who are positive for infection with the human papilloma virus (HPV).

12 Sep 2005

Vical and NIH to evaluate enhanced-delivery HIV vaccine

Vical Incorporated today announced plans to develop and evaluate electroporation-enhanced delivery of therapeutic and preventive DNA vaccines against HIV

12 Sep 2005

Inhaled-insulin drug Exubera - monitoring programme to be launched by Pfizer

Drug company Pfizer says it is all set to launch a patient-monitoring scheme in order to assess the safety of its novel inhaled-insulin drug Exubera, if the product is approved for use.

10 Sep 2005

Royal Pharmaceutical Society of Great Britain warns of internet medicines risk

The Royal Pharmaceutical Society of Great Britain has welcomed the Centre for Reform's report, Online pharmacy: patient choice or patient peril, and warns that people are dicing with danger if they use rogue internet websites to bypass safety rules and obtain medicines without a doctor’s prescription.

7 Sep 2005

Third-year medical students receive on average one gift or attend one activity sponsored by a pharmaceutical company per week

...and most believe that sponsored educational events are likely to be biased, according to an article in the September 7 issue of JAMA: The Journal of the American Medical Association, a theme issue on medical education.

7 Sep 2005

WHO urges responsible use of antimalarial medicines

In a new report published today, ''Susceptibility of Plasmodium Falciparum to Antimalarial Drugs,'' the World Health Organization (WHO) warns that as more and more people gain access to these life-saving malaria medicines, which combine a drug derived from the plant Artemisia annua with a second, synthetic drug, it is vital that countries closely monitor their effectiveness.

7 Sep 2005

Med Services Europe obtains rights to out-license portfolio of prescription pharmaceuticals

Med Services Europe GmbH, a "Virtual European Headquarters" for Pharmaceutical and Medical Manufacturers, announced that it has obtained rights to out-license a portfolio of prescription pharmaceuticals.

6 Sep 2005